Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to (exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 06-1562417 (I.R.S. Employer Identif ...

Financial Data and Key Metrics Changes - The company ended Q3 2023 with a cash balance of $100.63 million, down from $193.4 million at the end of the previous year [23] - For Q3 2023, the company recognized revenue of $24.3 million, resulting in a net loss of $64.5 million, while the net loss for the nine months of 2023 totaled $208.9 million [23] Business Line Data and Key Metrics Changes - The company is focusing on three key priorities: submitting a biologics license application for colorectal cancer, prioritizing clinical programs for rapid approval, and reallocating resources to achieve these goals [6][9] - The Phase II clinical trial in MSS-CRC has shown a 24% overall response rate, with a median overall survival rate exceeding 21 months, significantly better than the standard of care [11][19] Market Data and Key Metrics Changes - The company is addressing an urgent unmet need in the colorectal cancer market, particularly for patients with advanced disease, by initiating a compassionate use program [7][8] - The company is also expanding its clinical trials to include earlier lines of therapy, potentially changing treatment paradigms for colorectal cancer [12] Company Strategy and Development Direction - The company aims to submit its first biologics license application in mid-2024, focusing on late-stage colorectal cancer [6][10] - The strategic focus includes advancing clinical programs in refractory pancreatic cancer and new adjuvant settings in colorectal cancer [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential of Botensilimab to provide significant benefits over existing therapies, particularly in challenging cancer types [17][19] - The company is optimistic about securing additional cash through milestone payments and asset sales, which are expected to total approximately $200 million [9][10] Other Important Information - The company is in advanced discussions for potential structured financing and corporate collaborations with larger pharmaceutical or biotech companies [10][48] - Management emphasized the importance of rapid development and the need for substantial financial commitments from potential partners [48] Q&A Session Summary Question: When can we expect initial Phase II data for the MSS CRC study? - Management indicated that data from the first 70 patients has been disclosed, with further data needing cleanup before publication, ideally around the time of the BLA submission [27] Question: What is the regulatory bar for the randomized CRC study? - The company needs to demonstrate a meaningful improvement over standard care, with current response rates showing a significant advantage [32] Question: What is the updated cash guidance? - The company expects a cash burn of approximately $40 million for Q4 and anticipates bringing in around $200 million through non-stock issuance transactions by mid-next year [38] Question: What is the plan for CRC patients in the Phase III confirmatory study? - The company is exploring options for both second and first-line studies, with ongoing discussions with the FDA to determine the best path forward [40][51]

Agenus Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 (exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Del ...

Agenus Inc. (NASDAQ:AGEN) Q1 2023 Earnings Conference Call May 9, 2023 8:30 AM ET Company Participants Zack Armen - Head, IR Dr. Garo Armen - Chairman & CEO Dr. Steven O'Day - Chief Medical Officer Christine Klaskin - Vice President of Finance Conference Call Participants Emily Bodnar - H.C. Wainwright Mike King - EF Hutton Mayank Mamtani - B. Riley Matt Phillips - William Blair Operator Good day, and welcome to the Agenus First Quarter 2023 Financial Results Conference Call. All lines have been placed on m ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) De ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-29089 Agenus Inc. (exact name of registrant as specified in its charter) Delaware 06-1562417 (State or other jurisdiction of (I.R.S. Employer i ...

Agenus Inc. (NASDAQ:AGEN) Q4 2022 Results Conference Call March 14, 2023 8:30 AM ET Company Participants Zack Armen - Head, Investor Relations Dr. Garo Armen - Chairman and Chief Executive Officer Dr. Steven O'Day - Chief Medical Officer Christine Klaskin - Vice President of Finance Conference Call Participants Matt Phillips - William Blair Mayank Mamtani - B. Riley Emily Bodnar - H.C. Wainwright Mike King - EF Hutton David Dai - SMBC Kelly Shi - Jefferies Operator Thank you for holding and welcome, everyon ...

d Q January 2023 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding Agenus', MiNK's, and SaponiQx's clinical development and regulatory plans (including the scope of any regulatory approval and the ability to obtain priority review) and timelines for product candidates including balstilimab, zalifrelimab, botensilimab, AGEN1327, AGEN1777, AGEN2373, AGEN1571, and A ...

Agenus Inc. (NASDAQ:AGEN) Q3 2022 Results Conference Call November 8, 2022 8:30 AM ET Company Participants Nico Frelick - Investor Relations Dr. Garo Armen - Chairman and Chief Executive Officer Christine Klaskin - Vice President of Finance Dr. Steven O'Day - Chief Medical Officer Dhan Chand - Scientific Director, Head of Drug Discovery Conference Call Participants David Dye - SNBC Matt Phipps - William Blair Mayank Mamtani - B. Riley Securities Kelly Shi - Jefferies Operator Thanks for holding, and welcome ...